CU24340B1 - Derivados de acetamidas fluoradas para el tratamiento del vih - Google Patents
Derivados de acetamidas fluoradas para el tratamiento del vihInfo
- Publication number
- CU24340B1 CU24340B1 CUP2015000096A CU20150096A CU24340B1 CU 24340 B1 CU24340 B1 CU 24340B1 CU P2015000096 A CUP2015000096 A CU P2015000096A CU 20150096 A CU20150096 A CU 20150096A CU 24340 B1 CU24340 B1 CU 24340B1
- Authority
- CU
- Cuba
- Prior art keywords
- hiv
- derivatives
- acetamids
- fluorated
- treatment
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 241000712907 Retroviridae Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000003869 acetamides Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361771655P | 2013-03-01 | 2013-03-01 | |
US201361857636P | 2013-07-23 | 2013-07-23 | |
PCT/US2014/019663 WO2014134566A2 (en) | 2013-03-01 | 2014-02-28 | Therapeutic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20150096A7 CU20150096A7 (es) | 2016-07-29 |
CU24340B1 true CU24340B1 (es) | 2018-05-08 |
Family
ID=50382584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2015000096A CU24340B1 (es) | 2013-03-01 | 2014-02-28 | Derivados de acetamidas fluoradas para el tratamiento del vih |
Country Status (37)
Country | Link |
---|---|
US (4) | US9951043B2 (cs) |
EP (3) | EP3409667B1 (cs) |
JP (5) | JP6519486B2 (cs) |
KR (1) | KR102229989B1 (cs) |
CN (2) | CN108516974A (cs) |
AP (1) | AP2015008717A0 (cs) |
AU (3) | AU2014223973B2 (cs) |
BR (1) | BR112015021027B1 (cs) |
CA (2) | CA3007006A1 (cs) |
CL (1) | CL2015002445A1 (cs) |
CR (2) | CR20190504A (cs) |
CU (1) | CU24340B1 (cs) |
CY (1) | CY1121047T1 (cs) |
DK (1) | DK2961742T3 (cs) |
EA (1) | EA035127B1 (cs) |
ES (2) | ES2887578T3 (cs) |
HK (3) | HK1222169A1 (cs) |
HR (1) | HRP20181679T1 (cs) |
HU (1) | HUE039521T2 (cs) |
IL (1) | IL240519B (cs) |
LT (1) | LT2961742T (cs) |
MD (1) | MD20150092A2 (cs) |
MX (1) | MX2015011478A (cs) |
MY (1) | MY195364A (cs) |
NZ (3) | NZ728537A (cs) |
PE (2) | PE20191461A1 (cs) |
PH (1) | PH12015501881A1 (cs) |
PL (2) | PL2961742T3 (cs) |
PT (2) | PT2961742T (cs) |
RS (1) | RS57718B1 (cs) |
SG (2) | SG10201710764YA (cs) |
SI (2) | SI3409667T1 (cs) |
TW (2) | TWI706945B (cs) |
UA (1) | UA120346C2 (cs) |
UY (1) | UY35362A (cs) |
WO (1) | WO2014134566A2 (cs) |
ZA (1) | ZA201506098B (cs) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
TWI706945B (zh) | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
WO2014144545A2 (en) * | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
JP6491321B2 (ja) | 2014-08-29 | 2019-03-27 | ギリアード サイエンシーズ, インコーポレイテッド | 抗レトロウイルス剤 |
US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
US20160145344A1 (en) * | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
PT3236972T (pt) | 2014-12-26 | 2021-09-24 | Univ Emory | Derivados antivirais n4-hidroxicitidina |
US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CA2983201A1 (en) | 2015-04-23 | 2016-10-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
AU2016250661B2 (en) * | 2015-04-23 | 2018-07-26 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
US20170040479A1 (en) | 2015-08-07 | 2017-02-09 | Solaero Technologies Corp. | Reliable interconnection of solar cells |
US20170081324A1 (en) * | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease |
US20190307776A1 (en) | 2016-06-30 | 2019-10-10 | Viiv Healthcare Uk (No. 5) Limited | Aza-substituted inhibitors of human immunodeficiency virus replication |
EP3478703A1 (en) | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Triterpenoid inhibitors of human immunodeficiency virus replication |
JP6936820B2 (ja) | 2016-06-30 | 2021-09-22 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのアザデカリン誘導体 |
FI3597646T3 (fi) * | 2016-08-19 | 2023-09-07 | Gilead Sciences Inc | Hi-virusinfektion profylaktiseen tai terapeuttiseen hoitoon käyttökelpoisia terapeuttisia yhdisteitä |
EA036921B1 (ru) * | 2017-02-10 | 2021-01-15 | Джилид Сайэнс, Инк. | Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич |
TW201906834A (zh) | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
TW202024061A (zh) * | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
AR112412A1 (es) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
US10836746B2 (en) * | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
TWI823164B (zh) | 2018-02-16 | 2023-11-21 | 美商基利科學股份有限公司 | 用於製備有療效化合物之方法及中間物 |
JP7307747B2 (ja) * | 2018-04-11 | 2023-07-12 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての4-オキソ-3,4-ジヒドロキナゾリン化合物 |
KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
US11958834B2 (en) * | 2018-08-09 | 2024-04-16 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
WO2020053811A1 (en) | 2018-09-14 | 2020-03-19 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
US11919897B2 (en) | 2018-09-20 | 2024-03-05 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
EA202190854A1 (ru) | 2018-10-24 | 2021-08-17 | ВАЙВ ХЕЛТКЕР ЮКей (№5) ЛИМИТЕД | Ингибиторы репликации вируса иммунодефицита человека |
JP7532354B2 (ja) | 2018-10-24 | 2024-08-13 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
ES2942998T3 (es) | 2018-10-25 | 2023-06-08 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de inmunodeficiencia humana |
WO2020089778A1 (en) | 2018-10-29 | 2020-05-07 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
EP3876942A1 (en) | 2018-11-05 | 2021-09-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
US20210395248A1 (en) | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
UY38559A (es) | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
WO2020222108A1 (en) | 2019-04-30 | 2020-11-05 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
CA3143136A1 (en) | 2019-06-19 | 2020-12-24 | VIIV Healthcare UK (No.5) Limited | Pyrido[2,3-d]pyrimidine derivatives as capsid inhibitors for treating human immunodeficiency virus |
JP2022551254A (ja) | 2019-10-01 | 2022-12-08 | ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
JP2022551256A (ja) | 2019-10-01 | 2022-12-08 | ビーブ、ヘルスケア、ユーケー、(ナンバー5)、リミテッド | ヒト免疫不全ウイルスの複製阻害剤 |
TW202128648A (zh) | 2019-10-04 | 2021-08-01 | 英商Viiv醫療保健英國(No 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
US20220370451A1 (en) | 2019-10-08 | 2022-11-24 | VIIV HEALTHCARE UK ( No. 5) LIMITED | Inhibitors of human immunodeficiency virus replication |
US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
TW202133858A (zh) | 2019-11-28 | 2021-09-16 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥 |
CA3162126A1 (en) * | 2019-11-29 | 2021-06-03 | Jiangsu Hengrui Medicine Co., Ltd. | Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof |
US20230142606A1 (en) * | 2020-01-30 | 2023-05-11 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic amino compounds |
EP4114527A1 (en) | 2020-03-06 | 2023-01-11 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
KR20220151655A (ko) * | 2020-03-06 | 2022-11-15 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제 |
CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司(Us) | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
EP4135702A1 (en) | 2020-04-15 | 2023-02-22 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
AU2021296607B2 (en) | 2020-06-25 | 2024-07-25 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
TW202313584A (zh) * | 2021-05-28 | 2023-04-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 稠合吡啶環衍生物的可藥用鹽、晶型及其製備方法 |
KR20240113832A (ko) | 2021-12-03 | 2024-07-23 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염 치료용 화합물 |
AU2022401696A1 (en) | 2021-12-03 | 2024-05-09 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
KR20240117588A (ko) | 2021-12-03 | 2024-08-01 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염 치료용 화합물 |
TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2010493T3 (pl) | 2006-04-12 | 2016-08-31 | Merck Sharp & Dohme | Pirydyloamidy jako antagoniści kanałów wapniowych typu t |
WO2009054984A1 (en) * | 2007-10-24 | 2009-04-30 | Merck & Co., Inc. | Heterocycle phenyl amide t-type calcium channel antagonists |
EP2212293A4 (en) | 2007-10-24 | 2010-12-01 | Merck Sharp & Dohme | ANTAGONISTS OF T-TYPE CALCIUM CHANNELS BASED ON HETEROCYCLIC AMIDE |
NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
PE20120616A1 (es) | 2009-02-25 | 2012-05-26 | Bigtec Private Ltd | Sondas y cebadores para la deteccion de chikungunya |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
US20110035387A1 (en) * | 2009-08-10 | 2011-02-10 | Telcordia Technologies, Inc. | System and method for the controlled introduction of noise to information filtering |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
WO2011143772A1 (en) | 2010-05-21 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Inhibitors of hiv replication |
NZ604598A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Naphth-2-ylacetic acid derivatives to treat aids |
TWI458711B (zh) | 2010-07-02 | 2014-11-01 | Gilead Sciences Inc | 治療性化合物 |
CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
EP3872076A1 (en) | 2011-03-23 | 2021-09-01 | Trevena, Inc. | Opioid receptor ligands and methods of using and making same |
WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
AU2012278976B2 (en) * | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
CN102863512B (zh) * | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
WO2013019653A1 (en) * | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
TWI480271B (zh) | 2012-04-20 | 2015-04-11 | Gilead Sciences Inc | 醫療性化合物 |
GB201213087D0 (en) | 2012-07-24 | 2012-09-05 | Medical Res Council | Inhibition of HIV-1 infection |
WO2014028931A2 (en) | 2012-08-17 | 2014-02-20 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
CA2896244C (en) | 2013-01-09 | 2017-07-04 | Gilead Sciences, Inc. | 5-membered heteroaryls and their use as antiviral agents |
WO2014110296A1 (en) | 2013-01-09 | 2014-07-17 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
TWI706945B (zh) * | 2013-03-01 | 2020-10-11 | 美商基利科學股份有限公司 | 供治療反轉錄病毒科病毒感染之治療性化合物 |
US20140296266A1 (en) | 2013-03-01 | 2014-10-02 | Gilead Sciences, Inc. | Therapeutic compounds |
GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
KR20160078382A (ko) | 2013-10-24 | 2016-07-04 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 면역결핍 바이러스 복제의 억제제 |
US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
JP6491321B2 (ja) | 2014-08-29 | 2019-03-27 | ギリアード サイエンシーズ, インコーポレイテッド | 抗レトロウイルス剤 |
US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
CA2983201A1 (en) | 2015-04-23 | 2016-10-27 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
AU2016250661B2 (en) | 2015-04-23 | 2018-07-26 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
JP6620763B2 (ja) * | 2017-01-16 | 2019-12-18 | マツダ株式会社 | 電動車両 |
-
2014
- 2014-02-27 TW TW108101371A patent/TWI706945B/zh active
- 2014-02-27 TW TW103106785A patent/TWI694071B/zh active
- 2014-02-28 BR BR112015021027-9A patent/BR112015021027B1/pt active IP Right Grant
- 2014-02-28 CR CR20190504A patent/CR20190504A/es unknown
- 2014-02-28 US US14/771,779 patent/US9951043B2/en active Active
- 2014-02-28 CA CA3007006A patent/CA3007006A1/en not_active Abandoned
- 2014-02-28 SG SG10201710764YA patent/SG10201710764YA/en unknown
- 2014-02-28 PL PL14712844T patent/PL2961742T3/pl unknown
- 2014-02-28 LT LTEP14712844.1T patent/LT2961742T/lt unknown
- 2014-02-28 WO PCT/US2014/019663 patent/WO2014134566A2/en active Application Filing
- 2014-02-28 DK DK14712844.1T patent/DK2961742T3/en active
- 2014-02-28 SG SG11201506929VA patent/SG11201506929VA/en unknown
- 2014-02-28 PL PL18181536T patent/PL3409667T3/pl unknown
- 2014-02-28 EP EP18181536.6A patent/EP3409667B1/en active Active
- 2014-02-28 MY MYPI2015002119A patent/MY195364A/en unknown
- 2014-02-28 PT PT14712844T patent/PT2961742T/pt unknown
- 2014-02-28 CN CN201810393664.7A patent/CN108516974A/zh active Pending
- 2014-02-28 CU CUP2015000096A patent/CU24340B1/xx unknown
- 2014-02-28 PE PE2019001438A patent/PE20191461A1/es unknown
- 2014-02-28 JP JP2015560381A patent/JP6519486B2/ja active Active
- 2014-02-28 PE PE2015001811A patent/PE20151749A1/es unknown
- 2014-02-28 NZ NZ728537A patent/NZ728537A/en unknown
- 2014-02-28 ES ES18181536T patent/ES2887578T3/es active Active
- 2014-02-28 HU HUE14712844A patent/HUE039521T2/hu unknown
- 2014-02-28 KR KR1020157026837A patent/KR102229989B1/ko active IP Right Grant
- 2014-02-28 EA EA201591457A patent/EA035127B1/ru unknown
- 2014-02-28 UA UAA201508564A patent/UA120346C2/uk unknown
- 2014-02-28 EP EP21184874.2A patent/EP3954679A3/en active Pending
- 2014-02-28 CA CA2901502A patent/CA2901502C/en active Active
- 2014-02-28 AP AP2015008717A patent/AP2015008717A0/xx unknown
- 2014-02-28 SI SI201431878T patent/SI3409667T1/sl unknown
- 2014-02-28 AU AU2014223973A patent/AU2014223973B2/en active Active
- 2014-02-28 RS RS20181186A patent/RS57718B1/sr unknown
- 2014-02-28 US US14/194,623 patent/US20140303164A1/en not_active Abandoned
- 2014-02-28 MD MDA20150092A patent/MD20150092A2/ro not_active Application Discontinuation
- 2014-02-28 NZ NZ742681A patent/NZ742681A/en not_active IP Right Cessation
- 2014-02-28 MX MX2015011478A patent/MX2015011478A/es active IP Right Grant
- 2014-02-28 SI SI201430847T patent/SI2961742T1/sl unknown
- 2014-02-28 ES ES14712844.1T patent/ES2688571T3/es active Active
- 2014-02-28 PT PT181815366T patent/PT3409667T/pt unknown
- 2014-02-28 NZ NZ631754A patent/NZ631754A/en unknown
- 2014-02-28 EP EP14712844.1A patent/EP2961742B1/en active Active
- 2014-02-28 CN CN201480020587.0A patent/CN105705500B/zh active Active
- 2014-03-05 UY UY0001035362A patent/UY35362A/es not_active Application Discontinuation
-
2015
- 2015-08-12 IL IL240519A patent/IL240519B/en active IP Right Grant
- 2015-08-21 ZA ZA2015/06098A patent/ZA201506098B/en unknown
- 2015-08-26 PH PH12015501881A patent/PH12015501881A1/en unknown
- 2015-08-31 CL CL2015002445A patent/CL2015002445A1/es unknown
- 2015-09-01 CR CR20150454A patent/CR20150454A/es unknown
-
2016
- 2016-06-07 HK HK16106521.7A patent/HK1222169A1/zh unknown
- 2016-11-22 AU AU2016262671A patent/AU2016262671B2/en active Active
- 2016-12-22 HK HK18114165.0A patent/HK1260892A1/zh unknown
- 2016-12-22 HK HK16114621A patent/HK1226078B/zh unknown
-
2018
- 2018-03-02 US US15/910,083 patent/US20180273508A1/en not_active Abandoned
- 2018-06-15 JP JP2018114786A patent/JP6893899B2/ja active Active
- 2018-09-12 CY CY181100946T patent/CY1121047T1/el unknown
- 2018-10-15 AU AU2018247348A patent/AU2018247348A1/en not_active Abandoned
- 2018-10-15 HR HRP20181679TT patent/HRP20181679T1/hr unknown
-
2019
- 2019-08-16 JP JP2019149366A patent/JP2019214599A/ja not_active Withdrawn
-
2020
- 2020-05-26 US US16/882,804 patent/US20210009555A1/en active Pending
-
2021
- 2021-10-29 JP JP2021177617A patent/JP2022009742A/ja not_active Withdrawn
-
2023
- 2023-05-31 JP JP2023090106A patent/JP2023101723A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24340B1 (es) | Derivados de acetamidas fluoradas para el tratamiento del vih | |
CO2019001379A2 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih . | |
UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
UY35263A (es) | Compuestos terapéuticos | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
CO2018000660A2 (es) | Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol | |
CO2017007355A2 (es) | Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b | |
CR20150313A (es) | Composiciones farmacéuticas | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
UY36648A (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
UY36212A (es) | Moduladores de receptores tipo toll para el tratamiento del vih | |
NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
CR20140231A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
CR20170279A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
BR112017020837A2 (pt) | compostos de carbamoilpiridona policíclicos e seu uso farmacêutico | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
ECSP11011310A (es) | Análogos carba - nucleósido para tratamiento antiviral | |
CL2017000714A1 (es) | Composiciones farmacéuticas de acción prolongada | |
CU24525B1 (es) | Derivado de quinoleína para tratar y prevenir infecciones virales | |
CU24519B1 (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
CL2014000393A1 (es) | Compuestos derivados de benzofurano y sus sales, como inhibidores del virus de hepatitis c; composicion farmaceutica que los comprende; y su uso para el tratamiento o la prevencion de una infeccion por el virus de hepatitis c o de una enfermedad asociada con dicha infeccion. | |
CO2021012579A2 (es) | Compuestos útiles en la terapia del vih |